Invitae Pharmacogenomics Panel Mental Health Expansion

Invitae has expanded its Pharmacogenomics Panel to include genes associated with differential response to mental health drugs. While the PGx panel analyzes drug response-associated variants in 38 genes, the mental health-specific panel aligns with some payor coverage that limits the number of genes covered in this setting, according to the firm. The test's treatment guidance is based on the latest PGx guidelines and published evidence, Invitae added. In addition to helping personalize mental health treatment, the company's testing service also guides therapeutic strategies for patients in the areas of high-risk primary care, cardiology, endocrinology, pain management, and oncology. As part of the expanded testing service, physicians will also have access to Invitae's YouScript clinical decision support tool.